subject: Campral A Boon For Treatment Of Alcohol Dependence [print this page] INTRODUCTION
Alcohol addiction is one of the most dangerous realities that the current society is facing. To get rid of this obsession for an individual is far more difficult. In such case, the drug campral proves to be a boon which is used for treating alcohol dependence. The generic name of campral is acamprosate. The drug was approved by United States Food and Drug Association in July 2004, even though is extensively used for long time in many European countries. It is estimated that more than 1.5 million individuals are successfully treated with the help of this drug.
In order attain optimum results from campral it is necessary for an individual to follow the alcoholism treatment plan strictly, which mainly includes behavioural and mental counselling. In United States of America it is manufactured and marketed by Forest Laboratories and another company Merck KGaA markets it outside USA.
It helps to stabilize the chemical balance of the brain which gets readily affected by the consumption of alcohol i.e. it provides neuro protection. Basically campral is used to treat a person who has recently quit the consumption of alcohol and wants to stay away from it. It is said that the drug is not proved to be helpful to people who have not left the obsession of alcoholism. It works by blocking the glutamatergic N-methyl-D-aspartate receptors and activating gamma-aminobutyric acid type A receptors. Several studies have been conducted to study the effectiveness of this drug on individuals who have quit the alcohol in the near past, and it is proven to be very helpful in satisfying the need of abstinence from alcohol.
CLINICAL STUDIES
In the recent studies, naltrexone has shown consistent results over individuals who want to stay away from alcoholism, while campral has not delivered the fruitful results relative to placebo. Researchers believed that the combination of naltrexone and campral can prove to be a helpful remedy. To verify this, 169 alcohol dependent individuals were considered for a study. They were given 50 mg of naltrexone and 1998 mg of acamprosate per day for 12 weeks. All subjects were given manual agreement therapy which mainly focuses on misperception and dilemma about the drug. Analyses of 94 subjects who fully completed the study, with 80% of agreement showed no significant effect of the treatment. The treatment effects were identified after measuring the outcome of Alcohol Dependence Scale and Depression Anxiety Stress Scale. A beneficial treatment effect was noticed on time to first relapse with no depression allocated to naltrexone (n=56; P
by: Led
welcome to Insurances.net (https://www.insurances.net)
